公开(公告)号：US20050131046A1

公开(公告)日：2005-06-16

申请号：US10989514

申请日：2004-11-17

Applicant: A.K. Aberg ,  John McCullough ,  Emil Smith

Inventor： A.K. Aberg ,  John McCullough ,  Emil Smith

IPC: A61K31/451 ,  A61K31/4545 ,  A61K45/06 ,  A61K31/4172

CPC classification number: A61K31/4545 ,  A61K31/451 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.

Abstract translation: 公开了使用氯雷他定的代谢衍生物DCL用于治疗过敏性鼻炎和其他疾病的方法，同时避免与其他非镇静抗组胺剂相关的副作用的伴随的责任。

公开(公告)号：US20050101534A1

公开(公告)日：2005-05-12

申请号：US10712849

申请日：2003-11-13

Applicant: Charles Zepp ,  Donald Heefner ,  Paul Rubin ,  Mark Currie

Inventor： Charles Zepp ,  Donald Heefner ,  Paul Rubin ,  Mark Currie

IPC: A61K31/17 ,  A61K31/495 ,  A61P27/16 ,  A61K38/17

CPC classification number: A61K31/17 ,  A61K31/495

Abstract: Ototoxic side-effects have either limited the application of an important group of antibiotics, aminoglycoside antibiotics, or have added further burden to those who have to resort to platinum-containing antineoplastic agents to treat life-threatening tumors. The present invention discloses pharmaceutical compositions that prevent or treat the ototoxic side-effects of aminoglycoside antibiotics and platinum-containing antineoplastic agents. The otoprotective compositions disclosed herein can also be used to treat noise induced hearing loss.

Abstract translation: 耳毒性副作用限制了一组重要的抗生素，氨基糖苷类抗生素的应用，或者为那些不得不使用含铂抗肿瘤剂治疗危及生命的肿瘤的人增加了进一步的负担。 本发明公开了预防或治疗氨基糖苷类抗生素和含铂抗肿瘤剂的耳毒性副作用的药物组合物。 本文公开的保护性组合物也可用于治疗噪声引起的听力损失。

公开(公告)号：US20050009798A1

公开(公告)日：2005-01-13

申请号：US10633086

申请日：2003-08-01

Applicant: Mark Currie ,  Steve Jones ,  Paul Grover ,  Chris Senanayake ,  Q. Fang

Inventor： Mark Currie ,  Steve Jones ,  Paul Grover ,  Chris Senanayake ,  Q. Fang

IPC: A61K31/573 ,  A61K31/58 ,  A61P5/44 ,  C07J5/00

CPC classification number: A61K45/06 ,  A61K31/137 ,  A61K31/56 ,  A61K31/573 ,  A61K31/58 ,  Y10S514/87 ,  A61K2300/00

Abstract: Compositions containing β2 adrenergic agonists in combination with carbonates and carbamates of the formula and in combination with related steroid carbonates and carbamates are disclosed. The compositions are useful for treating bronchospasm, for inducing bronchodilation and for treating rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) and inflammatory diseases, particularly by inhalation.

Abstract translation: 公开了含有β2肾上腺素能激动剂与下式的碳酸酯和氨基甲酸酯并与相关的类固醇碳酸酯和氨基甲酸酯组合的组合物。 该组合物可用于治疗支气管痉挛，用于诱发支气管扩张和治疗鼻炎，哮喘和慢性阻塞性肺疾病（COPD）和炎性疾病，特别是通过吸入治疗。

公开(公告)号：US20040225020A1

公开(公告)日：2004-11-11

申请号：US10848069

申请日：2004-05-19

Applicant: Sepracor Inc.

Inventor： John R. McCullough ,  Paul D. Rubin

IPC: A61K031/137

CPC classification number: A61K31/137 ,  A61K31/135

Abstract: Methods and compositions are disclosed utilizing the optically pure (null)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

Abstract translation: 公开了使用安非他酮的光学纯的（ - ） - 异构体来帮助戒烟，治疗吸烟和尼古丁成瘾以及治疗疼痛的方法和组合物，包括但不限于慢性疼痛，神经性疼痛和反射性交感神经营养不良 ，以及其他疾病如发作性睡病，慢性疲劳综合征，纤维肌痛，季节性情感障碍和经前期综合征，同时避免与外消旋安非他酮相关的不良影响。

公开(公告)号：US20040171647A1

公开(公告)日：2004-09-02

申请号：US10796354

申请日：2004-03-08

Applicant: Sepracor Inc.

Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

IPC: A61K031/4439

CPC classification number: A61K31/4439 ,  A61K31/00

Abstract: Methods and compositions are disclosed utilizing optically pure S(null)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(null) isomer is also useful for the treatment of gastroesophageal reflux. S(null)rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Abstract translation: 公开了使用光学纯的S（ - ）雷贝拉唑治疗人体溃疡的方法和组合物，同时显着减少与雷贝拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的S（ - ）异构体也可用于治疗胃食管反流。 S（ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

公开(公告)号：US20040092481A1

公开(公告)日：2004-05-13

申请号：US10693980

申请日：2003-10-28

Applicant: Sepracor, Inc.

Inventor： Thomas P. Jerussi

IPC: A61K031/724 ,  A61K031/137 ,  A61K031/519

CPC classification number: A61K31/50 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K31/40 ,  A61K31/415 ,  A61K31/44 ,  A61K31/475 ,  A61K31/495 ,  A61K31/505 ,  A61K31/52 ,  A61K45/06 ,  A61K2300/00

Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

Abstract translation: 公开了用于治疗和预防疾病和病症的方法，例如但不限于：进食障碍; 体重增加; 肥胖; 过敏性肠综合征; 强迫症; 血小板粘附; 呼吸暂停 情感障碍，如注意力缺陷障碍，抑郁症和焦虑症; 男性和女性性功能障碍; 不安腿综合征 骨关节炎 药物滥用，包括尼古丁和可卡因成瘾; 发作性睡病 疼痛如神经性疼痛，糖尿病性神经病和慢性疼痛; 偏头痛 脑功能障碍; 慢性疾病如经前期综合征; 和失禁。 还公开了药物组合物和剂型，其包含外消旋或光学纯的西布曲明代谢物和任选的另外的药理活性化合物。

公开(公告)号：US20030195261A1

公开(公告)日：2003-10-16

申请号：US10395298

申请日：2003-03-25

Applicant: Sepracor Inc.

Inventor： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Qun K. Fang

IPC: A61K031/137

CPC classification number: A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutrarnine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.

Abstract translation: 公开了用于治疗和预防疾病和病症的方法，包括但不限于勃起功能障碍，情感障碍，体重增加，脑功能障碍，疼痛，强迫症，药物滥用，慢性障碍，焦虑，进食障碍 ，偏头痛和失禁。 所述方法包括施用多巴胺再摄取抑制剂和任选的另外的药理活性化合物。 还公开了包含多巴胺再摄取抑制剂和任选的另外的药理学活性化合物的药物组合物和剂型。 优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布睾胺代谢物及其药学上可接受的盐，溶剂化物和包合物。 优选的另外的药理活性化合物包括影响中枢神经系统的药物，例如5-HT <3> 拮抗剂。

公开(公告)号：US20030149304A1

公开(公告)日：2003-08-07

申请号：US10238204

申请日：2002-09-10

Applicant: Sepracor Inc.

Inventor： Gerald J. Tanoury ,  Chris H. Senanayake ,  Donald W. Kessler

IPC: A61K031/137 ,  C07C217/30

CPC classification number: A61K31/205 ,  C07B2200/13 ,  C07C231/24 ,  C07C233/25 ,  C07C233/43

Abstract: A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.

Abstract translation: 公开了制备R，R-福莫特醇L-酒石酸盐的高纯度盐的方法。 该方法通过重结晶新型多晶型物提供最热力学稳定的多晶型物。

公开(公告)号：US20020193378A1

公开(公告)日：2002-12-19

申请号：US10200510

申请日：2002-07-23

Applicant: SEPRACOR INC.

Inventor： Claude Cotrel ,  Gerard Roussel

IPC: A61K031/498

CPC classification number: C07D487/04

Abstract: Dextrorotatory isomer of 6-(5-chloro-2-pyridyl)-5-null(4-methyl-1-piperazinyl)carbonyloxynull-7-oxo-6,7-dihydro-5H-pyrrolonull3,4-bnullpyrazine, its preparation and pharmaceutical compositions containing it which are usable as tranquillisers and hypnotics.

Abstract translation: -6 - （5-氯-2-吡啶基）-5 - [（4-甲基-1-哌嗪基）羰氧基] -7-氧代-6,7-二氢-5H-吡咯并[3,4-b] 吡嗪，其制剂和含有它的药物组合物，其可用作镇静剂和催眠药

公开(公告)号：US20020143016A1

公开(公告)日：2002-10-03

申请号：US10040475

申请日：2002-01-09

Applicant: Sepracor, Inc.

Inventor： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Paul D. Rubin ,  Yaping Hong ,  Roger A. Bakale ,  Tingjian Xiang ,  Fran A. McConville

IPC: A61K031/4985

CPC classification number: A61K31/4985 ,  A61K31/498 ,  C07B2200/07 ,  C07D487/04

Abstract: The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (null)-N-desmethylzopiclone, and optically pure (null)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (null)-N-desmethylzopiclone, and optically pure (null)-N-desmethylzopiclone.